OBJECTIVES: New ovarian cancer biomarkers suitable for early disease diagnosis, prognosis or monitoring could improve patient management and outcomes. DESIGN AND METHODS: Nidogen-2 was measured by immunoassay in serum of 100 healthy women, 100 women with benign gynecological conditions and 100 women with ovarian carcinoma. RESULTS: Serum nidogen-2 concentration between normal and benign disease patients was not different (median, 13.2 and 12.1 mg/L, respectively). However, nidogen-2 concentration in serum of ovarian cancer patients was elevated (median, 18.6 mg/L; p<0.0001). Both nidogen-2 and CA125 were elevated more in serous histotypes of ovarian cancer and late state disease. Nidogen-2 and CA125 concentrations were strongly correlated. ROC curve analysis for nidogen-2 had an area under the curve (AUC) ranging from 0.73 to 0.83 but CA125 was superior (AUC ranging from 0.87 to 0.99). There was no complementarity between the two markers. CONCLUSIONS: Nidogen-2 is a new biomarker for ovarian cancer which correlates closely with CA125. Copyright 2009 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
OBJECTIVES: New ovarian cancer biomarkers suitable for early disease diagnosis, prognosis or monitoring could improve patient management and outcomes. DESIGN AND METHODS: Nidogen-2 was measured by immunoassay in serum of 100 healthy women, 100 women with benign gynecological conditions and 100 women with ovarian carcinoma. RESULTS: Serum nidogen-2 concentration between normal and benign diseasepatients was not different (median, 13.2 and 12.1 mg/L, respectively). However, nidogen-2 concentration in serum of ovarian cancerpatients was elevated (median, 18.6 mg/L; p<0.0001). Both nidogen-2 and CA125 were elevated more in serous histotypes of ovarian cancer and late state disease. Nidogen-2 and CA125 concentrations were strongly correlated. ROC curve analysis for nidogen-2 had an area under the curve (AUC) ranging from 0.73 to 0.83 but CA125 was superior (AUC ranging from 0.87 to 0.99). There was no complementarity between the two markers. CONCLUSIONS:Nidogen-2 is a new biomarker for ovarian cancer which correlates closely with CA125. Copyright 2009 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
Authors: Jae-Hoon Kim; Steven J Skates; Toshimitsu Uede; Kwong-kwok Wong; John O Schorge; Colleen M Feltmate; Ross S Berkowitz; Daniel W Cramer; Samuel C Mok Journal: JAMA Date: 2002-04-03 Impact factor: 56.272
Authors: J W Fox; U Mayer; R Nischt; M Aumailley; D Reinhardt; H Wiedemann; K Mann; R Timpl; T Krieg; J Engel Journal: EMBO J Date: 1991-11 Impact factor: 11.598
Authors: Yanhong Liu; Farrah Kheradmand; Caleb F Davis; Michael E Scheurer; David Wheeler; Spiridon Tsavachidis; Georgina Armstrong; Claire Simpson; Diptasri Mandal; Elena Kupert; Marshall Anderson; Ming You; Donghai Xiong; Claudio Pikielny; Ann G Schwartz; Joan Bailey-Wilson; Colette Gaba; Mariza De Andrade; Ping Yang; Susan M Pinney; Christopher I Amos; Margaret R Spitz Journal: J Thorac Oncol Date: 2016-01 Impact factor: 15.609
Authors: Davide Tamburro; Claudia Fredolini; Virginia Espina; Temple A Douglas; Adarsh Ranganathan; Leopold Ilag; Weidong Zhou; Paul Russo; Benjamin H Espina; Giovanni Muto; Emanuel F Petricoin; Lance A Liotta; Alessandra Luchini Journal: J Am Chem Soc Date: 2011-11-03 Impact factor: 15.419
Authors: Christian J Gröger; Markus Grubinger; Thomas Waldhör; Klemens Vierlinger; Wolfgang Mikulits Journal: PLoS One Date: 2012-12-10 Impact factor: 3.240